Epalinges, Switzerland
Aspivix, founded in 2015, is a Swiss medical device company with a mission to innovate in the realm of women's health, particularly gynecology. Their breakthrough product, Carevix™, represents a significant advancement in gynecological care by being the first suction cervical stabilizer clinically proven to substantially reduce pain and bleeding during procedures like IUD insertions and hysteroscopies.
With Carevix™'s recent FDA clearance for the US and CE-Mark approval in Europe, the device has demonstrated its effectiveness with a pain reduction of up to 73% and bleeding reduced by up to 83%, as published in Contraception journal in 2023. Serving an unmet need in a market still reliant on outdated tools, Aspivix addresses a considerable demographic: over 120 million women undergoing procedures globally.
The company's latest financing round included a Fr.500.00K debt investment from the Foundation for Technological Innovation (FIT), underscoring confidence in its growth potential. As Aspivix continues to push boundaries, its innovative approach offers an attractive proposition for investors eager to drive change in the Biotechnology and Women's Health sectors.
